Worthing Facility Licence Renewal

RNS Number : 8485F

Allergy Therapeutics PLC

30 April 2014

 



30 April 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Worthing Facility Licence Renewal

Allergy Therapeutics, the fully integrated specialty pharmaceutical company, announces that its Worthing facilities have recently been inspected by the MHRA and today received its Certificate of GMP Compliance.

Over the past seven years Allergy Therapeutics has invested over £10 million in the upgrade of its injectibles' facility. 
Today, over 210,000 allergy vaccines and diagnostic tests are manufactured each year at this site, with over 95% of sales made overseas.  In the past 12 months, products have been supplied to new markets such as the Baltic States and New Zealand.  The facilities have significant capacity to further increase output and operating efficiencies. 

Allergy Therapeutics employs around 200 people in Worthing and is proud of it trading heritage, spanning nearly 80 years.

Ian Postlethwaite, Finance Director at Allergy Therapeutics, commented:

"The significant enhancements we have made, combined with the highest quality values, means that our facilities are now prepared for producing clinical trial material for US trials.  We have a very committed work force in Worthing with a high level of specialist skills and technical expertise, and we feel immensely proud to be part of the high-tech UK manufacturing sector that is exporting products world-wide."

-Ends-

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director Bev Lees, Associate Supply Director
Peel Hunt LLP	[phone]
James Steel Clare Terlouw
FTI Consulting	[phone]
Simon Conway  / Mo Noonan / Victoria Foster-Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving sales in the prior financial year of £40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.  The Company is expanding its infrastructure into the Emerging Markets.

 

END

 

 

NRASEFEDUFLSEEL